<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123120</url>
  </required_header>
  <id_info>
    <org_study_id>1368-0010</org_study_id>
    <secondary_id>2016-004572-21</secondary_id>
    <nct_id>NCT03123120</nct_id>
  </id_info>
  <brief_title>A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy</brief_title>
  <official_title>Proof-of-concept Study of BI 655130 add-on Treatment in Patients With Mild-to-moderately Active Ulcerative Colitis During TNF Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this trial are safety and efficacy (proof-of-concept) of induction of
      mucosal healing by BI 655130 add-on therapy in patients with mild or moderate ulcerative
      colitis and persisting endoscopic activity despite pre-existing TNFi treatment.

      This trial will explore safety and efficacy of a dose of BI 655130 that was modelled to
      achieve the similar exposures as the highest exposures tested and found safe and tolerable in
      preceding single and multiple dose studies in healthy subjects, as add-on to pre-existing
      TNFi (Tumor necrosis factor inhibitor) treatment. Secondary and further objectives include
      assessment of the pharmacokinetic (PK) profile of BI 655130 and early exploration of specific
      biomarkers with potential usefulness to predict clinical efficacy or safety outcome or help
      understand BI 655130`s mode of action.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mucosal healing (MCS (Mayo Score) mESS (Modified endoscopic subscore) &lt;=1) at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission based on Mayo score (total MCS (Mayo Score) &lt;=2 points, and all subscores &lt;=1 point) at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological remission (Robarts (RHI (Robarts Histopathology Index)) score &lt;=6) at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission based on Mayo score (total MCS (Mayo Score) &lt;=2 points, and all subscores &lt;=1 point) at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal healing (MCS (Mayo Score) mESS (Modified endoscopic subscore) &lt;=1) at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological remission (Robarts (RHI) score &lt;=6) at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified clinical remission based on Mayo score (total modified MCS (Mayo Score)&lt;=2 and: RBS (Rectal Bleeding Subscore) =0, Stool Frequency Score (SFS) =0 or 1 and drop &gt;=1 from baseline, AND mESS (Modified endoscopic subscore) &lt;=1) at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified clinical remission based on Mayo score (total modified MCS (Mayo Score) &lt;=2 and: RBS (Rectal Bleeding Subscore) =0, SFS (Stool Frequency Score) =0 or 1 and drop &gt;=1 from baseline, AND mESS ((Modified endoscopic subscore) &lt;=1) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emerging adverse events</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>BI 655130</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655130</intervention_name>
    <description>12 weeks treatment</description>
    <arm_group_label>BI 655130</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>12 weeks treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  18 - 60 years at screening and randomisation

          -  Diagnosis of ulcerative colitis &gt;= 5 months prior to screening

          -  Receiving TNFi treatment with doses (i.e. dose and dosing interval) unchanged for &gt;= 4
             months prior to randomisation

          -  Mild or moderate disease activity, defined as total Mayo Score (MCS) (&lt;= 10)

          -  Further inclusion criteria apply

        Exclusion Criteria:

          -  Prior use of more than one different TNF inhibitor or vedolizumab

          -  Extensive colonic resection

          -  Evidence of infection with C. difficile or other intestinal pathogen &lt;28 days prior to
             screening

          -  Active or latent tuberculosis

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg Sygehus Syd</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Fallingborg</last_name>
      <phone>+45 97663560</phone>
      <email>jaf@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Kjeldsen</last_name>
      <phone>+45 41158986</phone>
      <email>jens.kjeldsen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Neurath</last_name>
      <phone>+49 (9131) 8535204</phone>
      <email>Markus.Neurath@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hasselblatt</last_name>
      <phone>+49 (761) 27034010</phone>
      <email>peter.hasselblatt@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Huber</last_name>
      <phone>+49 (40) 7410-57273</phone>
      <email>shuber@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Seidler</last_name>
      <phone>+49 (511) 5329427</phone>
      <email>Seidler.Ursula@MH-Hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Schreiber</last_name>
      <phone>+49 (431) 50015101</phone>
      <email>s.schreiber@mucosa.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Klaus</last_name>
      <phone>+49 (731) 50044609</phone>
      <email>jochen.klaus@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin 4</city>
        <zip>D04 T6F4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glen Doherty</last_name>
      <phone>35312214711</phone>
      <email>g.doherty@st-vincents.ie</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geert D'Haens</last_name>
      <phone>+31 (0)20 566 3534</phone>
      <email>g.dhaens@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus HF</name>
      <address>
        <city>Lørenskog</city>
        <zip>N-1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jørgen Jahnsen</last_name>
      <phone>+47 67966013</phone>
      <email>jorgen.jahnsen@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Ordas</last_name>
      <phone>+34932275400</phone>
      <email>Iordas@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Vera Mendoza</last_name>
      <phone>+34911916000</phone>
      <email>isabel.veramendoza@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Rivero</last_name>
      <phone>+34942203565</phone>
      <email>digrtm@humv.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belén Beltrán Niclos</last_name>
      <phone>+34961244000</phone>
      <email>belenbeltranniclos@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Kaser</last_name>
      <phone>01223768308</phone>
      <email>ak729@cam.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Selinger</last_name>
      <phone>0113 206 7549</phone>
      <email>Christian.selinger@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Irving</last_name>
      <phone>02071882499</phone>
      <email>peter.irving@gstt.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

